المؤلفون: Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Belleudi, Francesca, Noto, Alessia, De Vitis, Claudia, Pisanu, Maria Elena, Coluccia, Pierpaolo, Camerlingo, Rosa, Roscilli, Giuseppe, Ribas, Antoni, Di Napoli, Arianna, Torrisi, Maria Rosaria, Aurisicchio, Luigi, Ascierto, Paolo Antonio, Mancini, Rita, Ciliberto, Gennaro

المصدر: Oncotarget. 6(28)

مصطلحات موضوعية: Cancer, Biotechnology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Blotting, Western, Cell Line, Tumor, Drug Resistance, Neoplasm, Drug Synergism, Epitopes, Humans, Indoles, MAP Kinase Kinase 1, Melanoma, Mice, Mutation, Phosphorylation, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Proto-Oncogene Proteins c-akt, Pyridones, Pyrimidinones, Receptor, ErbB-3, Sulfonamides, Vemurafenib, Xenograft Model Antitumor Assays, melanoma, BRAF/MEK inhibitors, ErbB3 activation, Anti-ErbB3 antibodies, in vivo regrowth impairment, Receptor, erbB-3, Oncology and Carcinogenesis

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/7hf2c5gqTest

المؤلفون: Fattore, Luigi, Marra, Emanuele, Pisanu, Maria, Noto, Alessia, de Vitis, Claudia, Belleudi, Francesca, Aurisicchio, Luigi, Mancini, Rita, Torrisi, Maria, Ascierto, Paolo, Ciliberto, Gennaro

مصطلحات موضوعية: Melanoma, BRAF/MEK inhibitors, ErbB3 hyperphosphorylation, Anti-ErbB3 antibodies

العلاقة: http://www.translational-medicine.com/content/11/1/180Test

الإتاحة: http://www.translational-medicine.com/content/11/1/180Test

المؤلفون: Pierpaolo Coluccia, Debora Malpicci, Maria Rosaria Torrisi, Emanuele Marra, Francesca Belleudi, Arianna Di Napoli, Giuseppe Roscilli, Rosa Camerlingo, Rita Mancini, Antoni Ribas, Luigi Fattore, Maria Elena Pisanu, Alessia Noto, Paolo A. Ascierto, Gennaro Ciliberto, Claudia De Vitis, Luigi Aurisicchio

المصدر: Oncotarget, vol 6, iss 28
Oncotarget

مصطلحات موضوعية: MAPK/ERK pathway, Indoles, Receptor, ErbB-3, endocrine system diseases, MAP Kinase Kinase 1, Drug Resistance, braf/mek inhibitors, erbb3 activation, anti-erbb3 antibodies, in vivo regrowth impairment, melanoma, Epitope, Mice, Epitopes, ErbB-3, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, ERBB3, Phosphorylation, skin and connective tissue diseases, Sulfonamides, Tumor, Blotting, Melanoma, Antibodies, Monoclonal, Drug Synergism, Oncology, ErbB3 activation, Neuregulin, Western, Research Paper, Receptor, Proto-Oncogene Proteins B-raf, BRAF/MEK inhibitors, Pyridones, Blotting, Western, Oncology and Carcinogenesis, Pyrimidinones, Anti-ErbB3 antibodies, Biology, Antibodies, Cell Line, Cell Line, Tumor, medicine, Animals, Humans, Protein kinase B, neoplasms, Protein Kinase Inhibitors, Oncogene, Cell growth, medicine.disease, Xenograft Model Antitumor Assays, digestive system diseases, Vemurafenib, Drug Resistance, Neoplasm, Mutation, Cancer research, Neoplasm, Proto-Oncogene Proteins c-akt

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8931db007d9c3e434ddeb43aaf64620fTest
https://escholarship.org/uc/item/7hf2c5gqTest

المؤلفون: Maria Rosaria Torrisi, Francesca Belleudi, Rita Mancini, Emanuele Marra, Claudia De Vitis, Luigi Aurisicchio, Alessia Noto, Gennaro Ciliberto, Luigi Fattore, Maria Elena Pisanu, Paolo A. Ascierto

المساهمون: Dipartimento di Medicina Clinica e Molecolare, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Takis s.r.l, Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi 'Magna Graecia' di Catanzaro [Catanzaro, Italie] (UMG)-Campus Germaneto, Institut Pasteur, Fondation Cenci Bolognetti - Istituto Pasteur Italia, Fondazione Cenci Bolognetti, Réseau International des Instituts Pasteur (RIIP), Azienda Ospedaliera S. Andrea, Istituto Nazionale per lo studio e la cura dei Tumori, Naples, Italy

المصدر: Journal of Translational Medicine
Journal of Translational Medicine, BioMed Central, 2013, 11, pp.180. ⟨10.1186/1479-5876-11-180⟩

مصطلحات موضوعية: MAPK/ERK pathway, MESH: Signal Transduction, Skin Neoplasms, Receptor, ErbB-3, MAP Kinase Kinase 1, Receptor tyrosine kinase, 0302 clinical medicine, ERBB3, Enzyme Inhibitors, Phosphorylation, Vemurafenib, Medicine(all), 0303 health sciences, biology, anti-erbb3 antibodies, braf/mek inhibitors, erbb3 hyperphosphorylation, melanoma, MESH: Real-Time Polymerase Chain Reaction, MEK inhibitor, Melanoma, General Medicine, MESH: Gene Expression Regulation, Neoplastic, MESH: Drug Resistance, Neoplasm, 3. Good health, Gene Expression Regulation, Neoplastic, MESH: Cell Survival, MESH: Enzyme Inhibitors, 030220 oncology & carcinogenesis, MESH: Receptor, erbB-3, Neuregulin, MESH: MAP Kinase Kinase 1, medicine.drug, Signal Transduction, MESH: Cell Line, Tumor, Cell Survival, MESH: Melanoma, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Real-Time Polymerase Chain Reaction, General Biochemistry, Genetics and Molecular Biology, Antibodies, 03 medical and health sciences, Cell Line, Tumor, medicine, Humans, Autocrine signalling, 030304 developmental biology, MESH: Humans, MESH: Phosphorylation, Biochemistry, Genetics and Molecular Biology(all), Research, MESH: Antibodies, MESH: Skin Neoplasms, medicine.disease, Molecular biology, Proto-Oncogene Proteins c-raf, Drug Resistance, Neoplasm, Cancer research, biology.protein, MESH: Proto-Oncogene Proteins c-raf, MESH: Antineoplastic Agents

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6c15776a0ac14b32a782e9b6c94b4cTest
https://hal-riip.archives-ouvertes.fr/pasteur-01053843Test